SMMT

H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development

Retrieved on: 
Thursday, October 19, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Knowledge, Massachusetts General Hospital, SMMT, Harvard Medical School, Publishing, City of Hope, Medical director, Lung cancer, GRACE, Drug, Summit, Quality of life, City, Global resources dividend, Providence Health & Services, Medscape, University, Therapy, Patient, Hospital, UpToDate, Associate, Pharmaceutical industry, Medical device, Nursing, MD

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Howard “Jack” West, MD, has joined Summit Therapeutics as Vice President of Clinical Development focused on lung cancer.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Howard “Jack” West, MD, has joined Summit Therapeutics as Vice President of Clinical Development focused on lung cancer.
  • West brings a wealth of experience, and his knowledge in treating lung cancer patients is unrivaled,” stated Dr. Maky Zanganeh, Chief Executive Officer and President of the Company.
  • We are thrilled to welcome Jack to our team.”
    Dr. West joins Summit from City of Hope, one of the nation’s leading cancer treatment and research centers.
  • As a practicing physician, Dr. West has been a principal investigator in over 20 clinical trials in lung cancer.

Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer

Retrieved on: 
Monday, October 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Genentech, LLP, Drug development, Abstract, Harvard University, Pfizer, Data management, Drug, Pharmacyclics, Arena Pharmaceuticals, Therapy, SMMT, Quality of life, Lasso, PwC, Knowledge, Amgen, Biogen, AbbVie, Athenahealth, CFO, Stonehill College, Faculty, Risk, Jazz Pharmaceuticals, University, Cancer, Jazz, Trust, Nektar, Immunotherapy, CMO, Biostatistics, Information technology, Alnylam Pharmaceuticals, MD Anderson Cancer Center, Public health, Regulatory affairs, Nektar Therapeutics, Sale, Senior, Doctor of Philosophy, Licensed practical nurse, ARIAD Pharmaceuticals, Growth, Hematology, Patient, Management, Nursing, Pharmacovigilance, Robert Maki

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.
  • “Manmeet Soni has few peers in this industry, and his track record speaks for itself,” stated Dr. Maky Zanganeh, Chief Executive Officer and President of Summit.
  • “Leveraging his leadership and wisdom on a daily basis is a powerful addition to the already formidable Team Summit.
  • I am grateful for the trust he has displayed in Maky, me, and our team in joining our mission full-time.”
    Mr. Soni has over 20 years of financial and operational leadership experience and joins Summit from Reata Pharmaceuticals, Inc., where he was President, Chief Operating Officer, & Chief Financial Officer.

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023

Retrieved on: 
Wednesday, August 9, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Monoclonal antibody, US Food Sovereignty Alliance, Clinical trial, OS, Trae tha Truth, Quality of life, TKI, NSCLC, Immunotherapy, Lung cancer, PFS, ASCO, VEGF, Hair, American Society of Clinical Oncology, Patient, Investment, EGFR, Anemia, Annual general meeting, SMMT, Webcast, Knowledge, PD-1, FDA, Phase, Collaboration, Society, ORR, Pharmaceutical industry, Road, Security (finance), Cryptocurrency, Rare-earth element

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter and six months ended June 30, 2023.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter and six months ended June 30, 2023.
  • Summit intends to dose patients in the HARMONi-3 trial during the second half of 2023.
  • Net loss for the three and six months ended June 30, 2023 was $14.7 million and $557.1 million, respectively.
  • Operating cash outflow for the six months ended June 30, 2023 and 2022 was $42.4 million and $38.2 million, respectively.

Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023

Retrieved on: 
Wednesday, August 2, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, SMMT, Knowledge, Quality of life, Summit, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its second quarter 2023 financial results and provide an operational update for the Company on Wednesday, August 9, 2023, before the market opens.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its second quarter 2023 financial results and provide an operational update for the Company on Wednesday, August 9, 2023, before the market opens.
  • Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through Summit’s website www.smmttx.com .
  • Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position.
  • Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.

Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

Retrieved on: 
Sunday, June 4, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Histology, Progression-free survival, Cohort, Neoplasm, DOR, Survival, OS, Sun, Trae tha Truth, Lung cancer, Constipation, TKI, NSCLC, Paranal Observatory, Immunotherapy, PFS, Trial of the century, ASCO, ORR, VEGF, Hair, HKEX, American Society of Clinical Oncology, Patient, EGFR, Anaplastic lymphoma kinase, Anemia, Annual general meeting, TME, SMMT, Poster, PD-1, Phase, Summit, Tumor microenvironment, Society, Safety, ALK, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today from 8:00 to 11:00am at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today from 8:00 to 11:00am at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
  • AK112-201 (NCT04736823) is an open-label Phase II study evaluating ivonescimab plus chemotherapy for 174 patents across three cohorts of patients.
  • After a median follow-up time of 13.3 months, median overall survival (OS) was not reached; although, estimated 9-month OS was 93.2%.
  • Over 750 patients have been treated with ivonescimab across multiple clinical studies in different indications in China and Australia.

Ivonescimab Updated Data to be Featured at ASCO 2023

Retrieved on: 
Thursday, June 1, 2023
Oncology, Medical Supplies, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Metastasis, Sun, Lung cancer, TKI, NSCLC, Central Time, Paranal Observatory, Immunotherapy, Trial of the century, ASCO, VEGF, HKEX, American Society of Clinical Oncology, Patient, EGFR, Anaplastic lymphoma kinase, TME, Annual general meeting, SMMT, Poster, PD-1, Phase, Summit, Tumor microenvironment, Society, Safety, ALK, Pharmaceutical industry, Medical imaging

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
  • The poster with updated clinical data from Phase II clinical trials will be displayed on Sunday June 4 from 8:00 to 11:00am Central Time during the Lung Cancer – Non-Small Cell Metastatic Poster Session.
  • The poster provides updated data supporting promising anti-tumor activity of ivonescimab in first line advanced or metastatic NSCLC, while displaying that ivonescimab may have an acceptable safety profile in combination with platinum-doublet chemotherapy for patients with squamous or non-squamous advanced or metastatic NSCLC in this clinical study.
  • Over 750 patients have been treated with ivonescimab across multiple clinical studies in different indications in China and Australia.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Axys, Monoclonal antibody, US Foods, Interest, Crown Bioscience International, AbbVie, Quality of life, PDL, Rights, TKI, Research, NSCLC, Immunotherapy, Lung cancer, Forbes China Celebrity 100, Sale, Bayer Corporation, VEGF, Patient, Investment, EGFR, SMMT, Webcast, Knowledge, Entrepreneurship, PD-1, FDA, Woman, Summit, Collaboration, Phase, Compugen (company), Michelle, Pharmaceutical industry, Security (finance), Cryptocurrency, Management, Pfizer

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023.
  • The Collaboration and License Agreement with Akeso closed on January 17, 2023 after going effective following customary waiting periods.
  • In exchange for these rights, Summit committed to an upfront payment of $500 million, which was paid in two installments.
  • Operating cash outflow for the three month ended March 31, 2023 and 2022 was $13.1 million and $19.0 million, respectively.

Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

Retrieved on: 
Tuesday, May 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Progression-free survival, Lung cancer, TKI, NSCLC, Carboplatin, Immunotherapy, Institutional review board, PFS, Trial of the century, VEGF, Patient, EGFR, TME, SMMT, Neoplasm, PD-1, FDA, Courage, Phase, Pemetrexed, Tumor microenvironment, Safety, Pharmaceutical industry, Nursing, Medical imaging, Paranal Observatory

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the first United States-based patient has been enrolled in the Phase III HARMONi study.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the first United States-based patient has been enrolled in the Phase III HARMONi study.
  • HARMONi is a Phase III multiregional, randomized, double-blinded study.
  • Specifically, the study will compare ivonescimab combined with pemetrexed and carboplatin chemotherapies against a placebo plus pemetrexed and carboplatin.
  • Over 750 patients have been treated with ivonescimab across multiple clinical studies in China and Australia.

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)

Retrieved on: 
Wednesday, May 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, US Food Sovereignty Alliance, Quality of life, TKI, NSCLC, Paranal Observatory, Lung cancer, Immunotherapy, VEGF, Patient, EGFR, TME, SMMT, Knowledge, PD-1, FDA, Tumor microenvironment, Food, Safety, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has determined its first two indications in non-small cell lung cancer (NSCLC) in which to pursue Phase III clinical trials for its innovative, potential first-in-class bispecific antibody, ivonescimab.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has determined its first two indications in non-small cell lung cancer (NSCLC) in which to pursue Phase III clinical trials for its innovative, potential first-in-class bispecific antibody, ivonescimab.
  • “I am immensely proud of the speed and efficiency of our team to enable clinical trials for SMT112,” stated Robert W. Duggan, Chairman & Chief Executive Officer of Summit.
  • “I am particularly enthusiastic about the potential of ivonescimab: this shared enthusiasm is the impetus behind Team Summit’s rapid development to enter into multiple Phase III clinical trials with SMT112.
  • Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Tuesday, March 21, 2023
Legal, Professional Services, SMMT, Ethics, Suite, Security (finance)

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Summit Therapeutics Inc. (“Summit” or “the Company”) (NASDAQ: SMMT ) for potential breaches of fiduciary duty on the part of its directors and management.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Summit Therapeutics Inc. (“Summit” or “the Company”) (NASDAQ: SMMT ) for potential breaches of fiduciary duty on the part of its directors and management.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.